Codexis, Inc. provided revenue guidance for the full year of 2022. Total revenues are expected to be in the range of $152 million to $158 million, an increase of nearly 50% at the midpoint compared to 2021; excluding revenue from Pfizer in both periods, revenue growth is projected to be 10% or more.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.84 USD | +1.07% | -6.89% | -6.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.89% | 198M | |
+36.22% | 51.51B | |
-6.52% | 39.03B | |
+35.14% | 38.91B | |
-10.62% | 26.68B | |
+12.69% | 26.13B | |
-15.48% | 19.91B | |
+42.77% | 13.71B | |
+30.46% | 12.38B | |
-3.29% | 11.74B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Codexis, Inc. Provides Revenue Guidance for the Full Year of 2022